Locally advanced breast cancer in octogenarian women

Breast Cancer Research and Treatment

Volumn 89, Issue 1, 2005, Pages 81-90

  Mano, Max ^a   Fraser, Ghislaine ^a   McIlroy, Pauline ^a   Stirling, Lynne ^a   MacKay, Helen ^a   Ritchie, Diana ^a   Canney, Peter ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Elderly patients; Locally advanced breast cancer; Primary chemotherapy; Primary hormonal therapy; Primary radiotherapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; ANTIESTROGEN; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEMCITABINE; GROWTH FACTOR; HORMONE; LETROZOLE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; STEROID; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; AGED; ALOPECIA; BLOOD TOXICITY; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMORBIDITY; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; GENE OVEREXPRESSION; GERIATRIC CARE; HAND FOOT SYNDROME; HUMAN; INTERMETHOD COMPARISON; MASTECTOMY; MEDICAL DECISION MAKING; ONCOGENE NEU; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; POSTMENOPAUSE; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMANS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 13644256075     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-1003-y     Document Type: Review

References (106)

1. Mano M, Awada A: Primary chemotherapy for breast cancer. Ann Oncol, in press
2. Hortobagyi GN, Ames FC, Buzdar AU, et al.: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer; 62(12): 2507-2516, 1988
3. Perez CA, Graham ML, Taylor ME, et al.: Management of locally advanced carcinoma of the breast. I. Noninflammatory. Cancer 74(1 Suppl): 453-465, 1994
4. Kimmick GG, Balducci L: Breast cancer and aging. Clinical interactions. Hematol Oncol Clin North Am 14: 213-234, 2000
5. Singletary SE, Shallenberger R, Guinee VF: Breast cancer in the elderly. Ann Surg 218(5): 667-671, 1993
6. Jubelirer SJ, Larzo CR: The treatment of breast cancer in the elderly: a community hospital experience. W V Med J 94(6): 329-331, 1998
7. Busch E, Kemeny M, Fremgen A, Osteen RT, Winchester DP, Clive RE: Patterns of breast cancer care in the elderly. Cancer 78(1): 101-111, 1996
8. Bouchardy C, Rapiti E, Fioretta G, et al.: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21(19): 3580-3587, 2003
9. Brancato G, Gandolfo L, Privitera A, Donati M, Amodeo C: Locally advanced breast cancer in the elderly: a major challenge requiring effective and appropriate treatment. Tumori 88(6): 467-469, 2002
10. Glinski B, Pawlicki M, Reinfuss M, et al.: Multimodality treatment of noninflammatory stage IIIb breast cancer. J Surg Oncol 66(3): 179-185, 1997
11. Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL: The consequences of undertreating breast cancer in the elderly. J Am Coll Surg 192(6): 698-707, 2001
12. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM: Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 74: 1601-1606, 1994
13. McCarty KS Jr, Silva JS, Cox EB, et al.: Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann Surg 197: 123-127, 1983
14. Early Breast Cancer Trialists' Collaborative Group. 2000 analysis Overview results. Fifth Meeting of the Early Breast Cancer Trialists' Collaborative Group. Oxford, UK, 21-23 September, 2000
15. Carlson RW, Anderson BO, Chopra R, et al.: Global Summit Treatment Panel. Treatment of breast cancer in countries with limited resources. Breast J 9(Suppl 2): S67-S74, 2003
16. Nagadowska M, Kulakowski A: Breast cancer in elderly women: characteristics of the disease. Eur J Surg Oncol 17(6): 609-614, 1991
17. Allred DC, Harvey JM, Berardo M, et al.: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998
18. Ellis MJ, Coop A, Singh B, et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19(18): 3808-3816, 2001
19. Hoff PM, Valero V, Buzdar AU, et al.: Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 88(9): 2054-2060, 2000
20. Smith I, Dowsett M, on behalf of the IMPACT Trialists: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Br Cancer Res Treat 2003 (abstract 1)
21. Eiermann W, Paepke S, Appfelstaedt J, et al.: Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12(11): 1527-1532, 2001
22. Mouridsen H, Gershanovich M, Sun Y, et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19(10): 2596-2606, 2001
23. Bonneterre J, Buzdar A, Nabholtz JM, et al.: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9): 2247-2258, 2001
24. Milla-Santos A: Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) patients (pts). Proc Am Soc Clin Oncol 2002 (abstr 156)
25. Kaufmann M, Bajetta E, Dirix LY, et al.: Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clin Breast Cancer 1(Suppl 1): S15-S18, 2000
26. Paridaens R, Therasse P, Dirix L, et al.: First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) - EORTC 10951 in collaboration with the exemestane working group and NCIC. Eur J Cancer Suppl 2(3): 126, 2004 (abstr 241)
27. Robertson JF, Osborne CK, Howell A, et al.: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98(2): 229-238, 2003
28. Robertson J, Howell A, Abram P, Lichinitser MR, Elledge R: Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann Oncol 13(Suppl 5): 46, 2002
29. Harper-Wynne C, English J, Meyer L, et al.: Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. Br J Cancer 81(2): 316-322, 1999
30. Jodrell DI, Smith IE, Mansi JL, et al.: A randomised comparative trial of Mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. Br J Cancer 63(5): 794-798, 1991
31. George ML, Hale PC, Gumpert JR, Hogbin BM, Deutsch GP, Yelland A: The use of neoadjuvant CMF to avoid mastectomy. Eur J Surg Oncol 25(1): 50-53, 1999
32. Vallejo CT, Lacava JA, Perez JE, et al.: Prognostic factors in locally advanced breast carcinoma (LABC): randomized phase-II trial of 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) vs. cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Proc Am Soc Clin Oncol 22: 73, 2003 (abstr 293)
33. Bennett JM, Muss HB, Doroshow JH, et al.: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6(10): 1611-1620, 1988
34. Pavesi L, Preti P, Da Prada G, Pedrazzoli P, Poggi G, Robustelli della Cuna G: Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer. Anticancer Res 15(2): 495-501, 1995
35. Alonso MC, Tabernero JM, Ojeda B, et al.: A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat 34(1): 15-24, 1995
36. Lemaire M, Focan C, Desaive C, et al.: Neoadjuvant chemotherapy, with mitoxantrone, cyclophosphamide and fluorouracil, in operable breast cancer of intermediate stage: first results of a phase II study in 40 patients. Bull Cancer 79(9): 883-891, 1992
37. O'Brien ME, Wigler N, Inbar M, et al.: CAELYX Breast Cancel-Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/ Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol, in press
38. Srimuninnimit V, Sinlaratana P, Bhothisuwan K, et al.: Phase II study with the combination of pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide (CC) in locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 22: 21/70a, 2002 (abstr 279)
39. Batist G, Ramakrishnan G, Rao CS, et al.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19(5): 1444-1454, 2001
40. Henderson IC, Allegra JC, Woodcock T, et al.: Rando-mized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7(5): 560-571, 1989
41. Aas T, Geisler S, Paulsen T, et al.: Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncol 35(Suppl 5): 5-8, 1996
42. Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8): 2672-2685, 1998
43. Barni S, Archili C, Lissoni P, Paolorossi F, Crispino S, Tancini G: A weekly schedule of epirubicin in pretreated advanced breast cancer. Tumori 79(1): 45-48, 1993
44. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19(22): 4224-4237, 2001
45. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R: Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 73(1): 85-88, 2002
46. Kimura M, KKBCOG: Weekly paclitaxel as neoadjuvant chemotherapy (NAC) for breast cancer (BC). Proc Am Soc Clin Oncol 22: 77, 2003 (abstr 307)
47. D'hondt R, Paridaens R, Wildiers H, et al.: Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 15(4): 341-346, 2004
48. Estevez LG, Cuevas JM, Anton A, et al.: Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 9(2): 686-692, 2003
49. Vogel C, O'Rourke M, Winer E, et al.: Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10(4): 397-402, 1999
50. Fumoleau P, Delgado FM, Delozier T, et al.: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11(7): 1245-1252, 1993
51. Smith IE, A'Hern R, Coombes G, et al.: A randomised neoadjuvant chemotherapy trial of vinorelbine/epirubicin (VE) vs standard doxorubicin/cyclophosphamide (DC) in patients with ≥3 cm diameter operable breast cancer (TOPIC 2). Proc Am Soc Clin Oncol 22: 21, 2003 (abstr 83)
52. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62(1): 2-8, 2002
53. Possinger K, Kaufmann M, Coleman R, et al.: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10(2): 155-162, 1999
54. Silva A, Gonzalez H, Perez M, et al.: Neoadjuvant gemcitabine plus epirubicin in locally advanced breast cancer: evidence of activity in a phase II study. Proc Am Soc Clin Oncol 22: 21/51b, 2002 (abstr 2015)
55. Gomez H, Kahatt C, Falcon S, et al.: A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report. Semin Oncol 28(3 Suppl 10): 57-61, 2001
56. O'shaughnessy JA, Blum J, Moiseyenko V, et al.: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9): 1247-1254, 2001
57. Biganzoli L, Goldhirsch A, Straehle C, et al.: Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). Ann Oncol 15(2): 207-210, 2004
58. Hutchins L, Green S, Ravdin P, et al.: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup trial INT 0102. Proc Am Soc Clin Oncol 17: 1a (abstract 2), 1998
59. Gianni L, Baselga J, Eiermann W, et al.: First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 2002 (abstr 132)
60. Fountzilas G, Polichronis A, Katsohis K, et al.: Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study. Oncology 53(2): 137-146, 1996
61. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al.: Burdens and benefits of adjuvant Cyclophosphamide, Methotrexate and Fluorouracil and Tamoxifen for elderly patients with breast cancer. The International Breast Cancer Study Group Trial VII. J Clin Oncol 18: 1412-1422, 2000
62. Repetto L, Vannozzi MO, Balleari E, et al.: Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells. Anticancer Res 19(1B): 879-884, 1999
63. Heidemann E, Stoeger H, Souchon R, et al.: Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 13(11): 1717-1729, 2002
64. Ehninger G, Weible KH, Heidemann EG, Waller HD: Mitoxantrone and cyclophosphamide in patients with advanced breast cancer. Cancer Treat Rep 68(10): 1283-1284, 1984
65. Repetto L, Miglietta L, Gardin G, et al.: Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. Breast Cancer Res Treat 30(2): 133-137, 1994
66. Gazet JC, Coombes RC, Ford HT, et al.: Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer 73(6): 758-762, 1996
67. Makris A, Powles TJ, Ashley SE, et al.: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9(11): 1179-1184, 1998
68. Gogas H, Papadimitriou C, Kalofonos HP, et al.: Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 13(11): 1737-1742, 2002
69. Ibrahim NK, Hortobagyi GN, Ewer M, et al.: Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol 43(6): 471-478, 1999
70. Green M, Buzdar A, Smith T, et al.: Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC - final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002 (abstr 135)
71. Chen C, Shen K, Lu J, Wu J, et al.: The combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of local advanced breast cancer. Proc Am Soc Clin Oncol 22: 57, 2003 (abstr 228)
72. Limentani SA, Brufsky AM, John E, Jahanzeb M: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support. Proc Am Soc Clin Oncol 22: 33, 2003 (abstr 131)
73. Adenis A, Vanlemmens L, Fournier C, Hecquet B, Bonneterre J: Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group. Breast Cancer Res Treat 40(2): 161-169, 1996
74. Rossi A, Gridelli C, Gebbia V, et al.: Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 23(2C): 1657-1664, 2003
75. Freyer G, Delozier T, Lichinister M, et al.: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21(1): 35-40, 2003
76. Estevez LG, Sanchez-Rovira P, Domine M, et al.: Biweekly docetaxel (D) and gemcitabine (G) as neoadjuvant chemotherapy in stage II and III breast cancer: a phase II trial and pharmacogenomic study. Proc Am Soc Clin Oncol 22: 61, 2003 (abstr 243)
77. Procopio G, Bajetta E, Gattinoni L, et al.: Safety and activity of capecitabine in elderly patients (pts) with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 22: 759, 2003 (abstr 3050)
78. Hess DD, Thuerlimann BJ, Pagani O, et al.: Phase I-II trial of capecitabine and vinorelbine in elderly patients (pts: >65 y) with metastatic breast cancer (MBC): SAKK 25/99 for the Swiss Group of Clinical Cancer Research, Berne, Switzerland. Proc Am Soc Clin Oncol 22: 21/274b, 2002 (abstr 2915)
79. Repetto L, Biganzoli L, Koehne CH, et al.: EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39(16): 2264-2272, 2003
80. Citron M, Berry D, Cirrincione C et al.: Superiority of dose-dense over conventional scheduling and equivalence of sequential vs. combination adjuvant chemotherapy for node-positive breast cancer (CALGB 9741, INT C9741). Br Can Res Treat 76 (Suppl 1): 532, December 2002 (abstr 15)
81. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792, 2001
82. Extra JM, Cognetti F, Maraninchi D, et al.: Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial. European Journal of Cancer Suppl 2(3): 125, 2004 (abstr 239)
83. Vogel CL, Cobleigh MA, Tripathy D, et al.: First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61(Suppl 2): 37-42, 2001
84. Burstein HJ, Harris LN, Marcom PK, et al.: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21(15): 2889-2895, 2003
85. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, et al.: Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 12(11): 1545-1551, 2001
86. O'Shaughnessy J, Vukelja SJ, Marsland T, Kimmel G, Ratnam S, Pippen J: Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer 3(Suppl 1): 17-20, 2002
87. Wolff AC, Bonetti M, Sparano JA, Wang M, Davidson NE: Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group trial E3198. Proc Am Soc Clin Oncol 22: 18, 2003 (abstr 70)
88. Bines J, Murad A, Lago S, et al.: Multicenter brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer. Proc Am Soc Clin Oncol 22: 67, 2003 (abstr 268)
89. Harris L, Burstein HJ, Gelman R, et al.: Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH+ Stage II/III breast cancer. Proc Am Soc Clin Oncol 22: 22, 2003 (abstr 86)
90. Balducci L, Extermann M, Carreca I: Management of breast cancer in the older woman. Cancer Control 8(5): 431-441, 2001
91. Vlastos G, Mirza NQ, Meric F, et al.: Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer 92(5): 1092-1100, 2001
92. Susann P, Susann PW, Ackerman S, Gibbons R, Hermann K, Kuhn P: Treatment outcomes for female octogenarians with breast cancer. Am Surg 65(5): 399-401, 1999
93. Fisher B, Redmond C, Fisher ER, et al.: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 328: 1581-1634, 1993
94. Semiglazov VF, Topuzov EE, Bavli JL, et al.: Primary (neoadjuvant) Chemotherapy and Radiotherapy Compared with Radio-therapy Alone in Stage IIB-IIIA Breast Cancer. Ann Oncol 5: 591-559, 1994
95. Scholl SM, Fourquet A, Asselain B, et al.: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery. Preliminary results of a randomised trial. Eur J Cancer 30A: 645-652, 1994
96. Badr el Din A, Coibion M, Guenier C, et al.: Local postoperative morbidity following pre-operative irradiation in locally advanced breast cancer. Eur J Surg Oncol 15(6): 486-489, 1989
97. Alund M, Granberg PO, Sundblad R. Surgical complications after radiation therapy for carcinoma of the breast. Surg Gynecol Obstet 144(2): 235-238, 1977
98. A Price, GR Kerr, A Rodger: Primary radiotherapy for T4 breast cancer. Clin Oncol 4: 217-221, 1992
99. WhelanT, MacKenzie R, Julian J, et al.: Randomised trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. JNCI 94(15): 1143-1150, 2002
100. Bates TD: A prospective clinical trial of post-operative radiotherapy delivered in three fractions per week versus two fractions per week in breast carcinoma. Clin Radiol 26(3): 297-304, 1975
101. Madleblatt J, Figueiredo M, Cullen J: Outcomes and quality of life following Breast Cancer treatment in older women: When, Why, How much, and What do women want? Health and Quality of Life Outcomes 1: 45, 2003
102. Balducci L, Extermann M. A practical approach to the older patient with cancer. Curr Probl Cancer 25(1): 6-76, 2001
103. Duthrie E: Physiology of aging: relevance to symptom perceptions and treatment tolerance. In: Balducci L, Lyman GH (eds) Comprehensive Geriatric Oncology. Harwood Academic publishers, Amsterdam
104. Balducci L, Yates J: General guidelines for the management of older patients with cancer. Oncology (Huntingt) 14(11A): 221-227, 2000
105. Balducci L, Extermann M, Carreca I. Management of breast cancer in the older woman. Cancer Control 8(5): 431-441, 2001
106. Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 3(10): 620-628, 2002